ALVO Alvotech IFRS Annual reports only
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1898416 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $586.32M | $489.68M |
| Cost of revenue | $235.56M | $185.31M |
| Gross profit | $350.76M | $304.37M |
| R&D expense | $184.19M | $171.31M |
| SG&A expense | $90.95M | $65.71M |
| Operating income | $78.21M | $69.64M |
| Interest expense | $149.19M | $303.17M |
| Pretax income | $136.35M | -$217.56M |
| Income tax | $108.43M | $14.30M |
| Net income | $27.92M | -$231.86M |
| EBITDA | $116.06M | $100.94M |
| EPS (basic) | 0.10 | -0.87 |
| EPS (diluted) | 0.10 | -0.87 |
| Weighted avg. shares (diluted) | 291.34M | 267.92M |
| Balance sheet | ||
| Cash & equivalents | $172.36M | $51.43M |
| Receivables | $69.74M | $160.22M |
| Inventory | $220.05M | $127.89M |
| Current assets | $574.01M | $455.02M |
| PP&E, netmay include right-of-use assets (IFRS) | $356.40M | $284.55M |
| Goodwill | $12.84M | $11.33M |
| Intangibles | $81.83M | $20.62M |
| Total assets | $1.49B | $1.22B |
| Current liabilities | $304.08M | $193.40M |
| Short-term debt | $36.92M | $32.70M |
| Long-term debt | $1.26B | $1.04B |
| Total debt | $1.30B | $1.07B |
| Total liabilities | $1.77B | $1.63B |
| Shareholders' equity | -$284.49M | -$412.77M |
| Net debt | $1.13B | $1.02B |
| Shares outstanding | 312.02M | 301.81M |
| Cash flow statement | ||
| Operating cash flow | -$50.20M | -$236.84M |
| Capital expenditure | $64.47M | $53.66M |
| Free cash flow | -$114.67M | -$290.50M |
| Investing cash flow | -$104.22M | -$18.87M |
| Financing cash flow | $270.83M | $297.31M |
| Depreciation & amortization | $37.85M | $31.30M |
| Stock-based compensation | $7.38M | $7.63M |
| Dividends paid | $0 | $0 |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.